<unk>  is a kinase inhibitor that is FDA approved for the the treatment of mantle cell lymphoma (MCL).   Common adverse reactions include anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising.
Acalabrutinib
Afatinib
Neratinib
Fostamatinib
Ibrutinib
Dasatinib
Brigatinib
Bosutinib